Novo Nordisk reported a successful Phase IIIb result for high-dose semaglutide in obese adults on 17 January, but analysts pointed out that while the data topped the weight loss demonstrated by the drug’s marketed 2.4mg dose of Wegovy, it fell short of the efficacy produced by Lilly’s Zepbound (tirzepatide) at the same time point in a Phase III study.
High-Dose Semaglutide Data A Mixed Bag For Novo Nordisk
Semaglutide 7.2mg bests placebo for weight loss at 72 weeks, but with efficacy lower than seen with Novo Nordisk’s CagriSema or Lilly’s Zepbound.
More from Clinical Trials
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
More from Therapy Areas
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.